Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Roles of mitochondrial DNA in dynamics of the immune response to COVID-19

Ata Mahmoodpoor a,1, Sarvin Sanae a,1, Zohreh Ostadi b, Maqsoud Eskandari b, Nazila Behrouzi b, Roqayeh Asghari b, Ahmad Zahirnia c, Nasim Sohrabifar b, *, Somayeh Kazeminasab a,*,2

a Research Center for Integrative Medicine in Aging, Aging research institute, Tabriz University of Medical Sciences, Tabriz, Iran
b Department of Anesthesiology and intensive care, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran
c Nasle Farda Health Foundation, Medical Genetic Laboratory, Tabriz, Iran
d Cardiovascular Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran

ARTICLE INFO

Edited by: Andre van Wijnen

Keywords:
mitDNA
ccf-mtDNA
Immune response
Inflammasome
COVID-19
SARS-CoV-2

ABSTRACT

Mitochondria dynamics have a pivotal role in many aspects of immune function. Viral infections affect mitochondrial dynamics and trigger the release of mitochondrial DNA (mtDNA) in host cells. Released mtDNA guides the immune response towards an inflammatory response against pathogens. In addition, circulating cell-free mtDNA (ccf-mtDNA) is considered an invaluable indicator for the prognosis and severity of infectious diseases. This study provides an overview of the role of mtDNA in the dynamics of the immune response to COVID-19. We focused on the possible roles of mtDNA in inducing the signaling pathways, and the inflammasome activation and regulation in SARS-CoV-2. Targeting mtDNA-related pathways can provide critical insights into therapeutic strategies for COVID-19.

1. Introduction

Coronavirus disease 2019 (COVID-19) as the result of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has had a catastrophic effect on the worldwide in the 21st century. The heterogeneous clinical spectrum, ranging from asymptomatic and mild upper respiratory tract illness to severe interstitial pneumonia with respiratory failure and even death, has introduced major challenges to the management of the COVID-19 pandemic (Wang et al. 2020). On the other hand, the differential immune response can contribute to the interindividual variations in the clinical manifestations of infectious diseases (Verhein et al. 2018).

Cell death ensures the survival of multicellular organisms against viral infections. Apoptosis and programmed necrosis limit pathogen replication in infected cells, while the release of damage-associated molecular patterns (DAMPs) promoting the inflammatory and innate responses in the host. DAMPs serve as endogenous ligands for interactions with Toll-like receptors (TLRs). TLRs play potent roles in inducing innate responses by promoting the expression of inflammatory cytokines (Upton and Chan 2014). Strong evidence suggests that mitochondria facilitate effector responses of the immune system. Mitochondrial DAMPs (mtDAMPs) are the potent immunological activators.

Abbreviations: mtDNA, mitochondrial DNA; ccf-mtDNA, circulating cell-free mitochondrial DNA; COVID-19, coronavirus disease 2019; SARS-CoV-2, severe acute respiratory coronavirus 2; DAMP, damage-associated molecular pattern; TLR, Toll-like receptor; Mt-DAMP, mitochondrial- damage-associated molecular pattern; ICU, intensive care unit; MAVS, mitochondrial antiviral signaling; HIV, human immunodeficiency virus; HPV, human papillomavirus; ISG, interferon stimulatory gene; ROS, reactive oxidative stress; ACE2, angiotensin-converting enzyme 2; TAPR5S2, transmembrane serine protease 2; PRR, pathogen-recognition receptors; MyD88, myeloid differentiation factor 88; cGAS, Cyclic guanosine monophosphate (GMP)-adenosine monophosphate (AMP) (cGAMP) synthase; STING, stimulator of interferon genes; ER, endoplasmic reticulum; CF, cystic fibrosis; COPD, chronic obstructive pulmonary disease; IPF, idiopathic pulmonary fibrosis; ORF, open reading frame; ND, nucleotide binding domain; LRR, leucine rich repeat; NLR, nucleotide binding domain and leucine rich repeat; mTRoS, mitochondrial reactive oxygen species; IncRNA, long non-coding RNA; AIN2, Absent in melanoma 2; GSDMD, gasdermin D; MSC, Mesenchymal stem cell.

* Corresponding authors: Nasle Farda Health Foundation, Medical Genetic Laboratory, Tabriz, Iran (S. Kazeminasab).
E-mail addresses: nasimehsohrabifar@yahoo.com (N. Sohrabifar), somayyekazeminasab@yahoo.com (S. Kazeminasab).

Contributed equally as the first author.

https://doi.org/10.1016/j.gene.2022.146681

Received 6 March 2022; Received in revised form 29 May 2022; Accepted 10 June 2022
Available online 18 June 2022
0378-1119/© 2022 Elsevier B.V. All rights reserved.
and released mtDAMPS such as N-formyl peptides, cytochrome c, cardiolin, and mitochondrial DNA (mtDNA) from the damaged or dying cells into the cytoplasm or circulation can influence immunity (Piantadosi 2020). Biological behaviors, such as cell necrosis and apoptosis can damage integrity of the cell membrane. Fragments of the mtDNA are subsequently released into the extracellular environment, such as blood or urine, and also stimulate systemic inflammation (De Gaetano et al. 2021). Several studies highlight the pivotal role of the mtDNA in inflammatory cell activation during viral infections (Kausar et al. 2020; Lai et al. 2018; West et al. 2011).

Increasing evidence supports the significant association between the level of ccf-mtDNA in plasma and mortality rate in critically ill patients (Harrington et al. 2019). Recent evidence suggests that mitochondrial dysfunction have an essential role in COVID-19 pathogenesis. The recent finding showed that high levels of ccf-mtDNA at the time of hospitalization elevated the probabilities of intensive care unit (ICU) admission and heightened the risk of death (Ayala et al. 2020; Saleh et al. 2020; Scozzi et al. 2021; Valdés-Aguayo et al. 2021). In the present review, we have attempted to highlight the possible roles of mtDNA as a mtDAMP in regulating the immune response and inflammatory reactions against COVID-19 infection. We have discussed the potential role of mtDNA in the induction of its related signaling pathways in cells infected with SARS-CoV-2. Moreover, we have pointed the possible role of mtDNA in inducing the biological processes and molecular mechanisms of inflammation in COVID-19.

2. Mitochondria trigger innate immunity during viral infections

Mitochondria are functionally versatile organelles and impacts cellular homeostasis, metabolism, and innate immune signaling. They play central role in the host defense against many diseases and are central participants in the induction of cell death, as well as in immune signaling pathways. Viral infections target mitochondrial function directly by viral proteins or physiological and biochemical alteration during the infections. Therefore, mitochondrial dynamics can be the major determinant of the outcome of viral infections (McWhirter and Maniatis 2005).

Activation of the immune responses through mitochondrial antiviral signaling (MATS) serves as the crucial cellular antiviral signaling pathway that induces the host’s innate immunity against viral infection (Belgnaoui et al. 2011; Seth et al. 2005). Innate immune responses are triggered by mtDAMPS which are released from damaged or dying cells into the circulation of the host (Elelsea and Lukacs 2021; Khan et al. 2015; West et al. 2011). Several potent immunological activators can induce the secretion of various proinflammatory cytokines causing cytokine storm (Hausser and Otterbein 2018; Itagaki et al. 2021) and increased plasma levels of extracellular mtDNA during various viral infection, such as HIV and HPV (Cossarizza et al. 2011; Feng et al. 2016).

The release of mtDNA into the cytoplasm and out into the extracellular milieu induces different pattern recognition receptors and innate immune responses (Riley and Tait 2020). These processes elicit the transcription of numerous interferon stimulatory genes (ISGs) that have potential and robust antiviral properties (Riley and Tait 2020). Some viruses can down-regulate interferon proinflammatory response by inducing mitochondrial fusion (Khan et al. 2015). Also, the inhibition of apoptosis as the result of imbalanced mitochondrial fission and fusion can ensure the survival of viral particles for longer (Ren et al. 2020). However, the maintenance of mitochondrial integrity is essential for adequate innate immune system responses and effective suppress of the cytokine storm in viral infections (Koshba et al. 2011).

3. Mitochondrial perspective of COVID-19

Clinical, immunological, and pathologic features of COVID-19 highlight the crucial role of the inflammatory state termed as the “cytokine storm” in the severity, and mortality rate of COVID-19 (Yuki et al. 2020). This inflammatory state is associated with diverse deleterious pathophysiological events such as reactive oxygen species (ROS) production, and dysregulation of iron homeostasis in COVID-19 patients. Mitochondrial dysfunction affects iron homeostasis and oxidative stress in viral infections (Drakesmith and Prentice 2008; Saleh et al. 2020; Silwal et al. 2020).

Mitochondrial dysfunction is strongly associated with aging. The speed and strength of immune response weaken due to the loss of certain immune tissues, as well as poorer energy metabolism at the cellular level (Wang and McLean 2022). Increased age correlates with the accumulation of mtDNA mutations which associate with the decline in mitochondrial levels and function (Chinnery et al. 2002). Given the evidence for mitochondrial involvement in aging and age-related diseases, mtDAMPS can be released from the mitochondrion and trigger immune and inflammatory responses in the elderly (Salminen et al. 2012). Also, mtDAMPS induce the inflammasome-associated caspases and mediate the maturation and release of the proinflammatory cytokines in advanced age (Furman et al. 2017). Steadily increase of circulating mtDNA in the cytoplasm of elderly people suggests a causal role of extracellular mtDNA in age-related immune activation (Pini et al. 2014). Based on our current knowledge, various age-related comorbidities such as diabetes, obesity, hypertension, dementia, coronary heart disease, chronic obstructive pulmonary disease, metabolic syndrome, and neurological diseases can play pivotal roles in COVID-19 severity and mortality amongst the elderly patients (Yang et al. 2020; Zhang et al. 2020a). The considerable role of mtDNA in inducing innate immunity and inflammatory responses can be the basic mechanism that contributes to the severity and lethality of COVID-19 in older patients (Ayala et al. 2020; Ganji and Reddy 2021).

The genome organization of SARS-CoV-2 is similar to other coronaviruses, which include a positive single-stranded RNA β-coronavirus. So, based on available data for the SARS-CoV-1, it seems that SARS-CoV-2 may hijack the mitochondria-targeted pathways to viral advantages such as survival, virulence and propagation (Saleh et al. 2020). Recent gene expression profiling of SARS-CoV-2 infection indicated that the imbalance in mitochondrial dynamics may stimulate viral replication by manipulating the immune responses and metabolism (Singh et al. 2020). The interaction between a number of SARS-CoV-2 and mitochondrial proteins promotes virus replication in cells. SARS-CoV-2 could also promote viral replication and immune evasion by inhibition of mitochondrial antiviral signalling protein (MATS) (Gordon et al. 2020).

SARS-CoV-2 cell entry depends on binding of the viral spike (S) proteins to cellular receptors and on S protein priming by host cell proteases. SARS-CoV-2 uses angiotensin-converting enzyme 2 (ACE2) and transmembrane serine protease 2 (TMPRSS2) for entry. It enters the cells by binding to ACE2 in a cholesterol-rich microdomain as the receptor (Hoffmann et al. 2020). Substantial genetic variation in the ACE2 gene is reported among world populations (Srivastava et al. 2020). Interestingly, ACE2 variation can also affect mitochondrial function (Shi et al. 2018). Thus, the mitochondrial function can be under the control of the variant and expression levels of the ACE2 gene (Singh et al. 2020). Understanding the relevance of mitochondrial dysfunction may shed light and elucidate the pathogenesis mechanisms and inter-individual variations in clinical manifestations of COVID-19. Also, the versatile nature of mitochondria can provide invaluable insights into the sophisticated mechanisms of immunomodulation, diagnostic and therapeutic targets to combat SARS-CoV-2 infection.
TLR9-MyD88-dependent activation of the NF-κB pathway induces the release of mtDNA as the result of mitochondrial dysfunction. The transportation of mtDNA fragments to endosomes exposes them to TLR9. TLR9 can trigger hyperinflammation and thrombotic complications during COVID-19 (Digard et al. 2020). In addition, activation of the genetic material of SARS-CoV-2 leads to TLR9 activation in many cells (Zhang et al. 2010). The high number of unmethylated CpG motifs in SARS-CoV-2 can elicit the immune response by binding to TLR9 (Barton et al. 2006; Zhang et al. 2010).

4.1. MtDNA-associated TLRs signaling pathways in COVID-19

Members of the TLR family belong to a class of pathogen-recognition receptors (PRR) that detect conserved viral nucleic acid that leads to innate immune activation and orchestration of the adaptive immune response (Carty and Bowie 2010).

The detail of molecular mechanisms of COVID-19 pathogenesis is still elusive. Therefore, our understanding of molecular signaling pathways of COVID-19 arises from the available data about SARS-CoV and Middle East respiratory syndrome coronavirus (MERS-CoV). Previous studies highlight the important role of type I interferon in the systemic inflammatory response during infection with SARS-CoV and MERS-CoV (Angelopoulou et al. 2020; Moreno-Eutimio et al. 2020).

Five mammalian Toll-like receptors (TLRs), including TLR3, TLR7, TLR8, TLR9, and TLR 13 can be activated by nucleic acid ligand. TLR9 was first identified as a DNA sensing receptor in immune cells. Specific affinity of TLR9 for unmethylated cytosine and guanine (CpG) nucleotides and the bacterial ancestry of mitochondria explain the mtDNA binding to TLR9. TLR9 activates the innate immune system by binding to mtDNA on immune cells. Therefore, in viral infections, when mtDNA is released into the circulation during mitochondria-induced cell death, it can elicit the immune response by binding to TLR9 (Barton et al. 2006; Zhang et al. 2010).

The high number of unmethylated CpG motifs in genetic material of SARS-CoV-2 leads to TLR9 activation in many cell types during COVID-19 (Digard et al. 2020). In addition, activation of TLR9 can trigger hyperinflammation and thrombotic complications caused by SARS-CoV-2 infection (Bezemer and Garssen 2021). TLR9 triggers an inflammatory downstream response, myeloid differentiation factor 88 (MyD88) (Cuevas et al. 2021). Recent findings demonstrated that an elevated level of ccf-mtDNA in endothelial cells promotes activation of TLR9 inflammatory responses, via NF-κB signaling and IL-6 production in SARS-CoV-2 infection (Costa et al. 2021; Fig. 1). Fabas et al. 2016). MAVs mediate the induction and regulation of interferon responses to viral infections (Ablasser and Hur 2020; Vazquez and Horner 2015). The following sections summarize the possible role of mtDNA in the dynamics of the immune signaling pathways in COVID-19.

4.2. MtDNA-associated cGAS-STING signaling pathway in COVID-19

Cyclic guanosine monophosphate (GMP)-adenosine monophosphate (AMP) (cGAMP) synthase (cGAS) is a cytosolic DNA sensor, which produces the second messenger cGAMP. This signaling pathway induces type I interferons and other immune mediators through activation of stimulator of interferon genes (STING) by cGAMP (Zhang et al. 2020c). STING is predominantly an endoplasmic reticulum (ER) - mitochondria associated membranes protein that can orchestrate diverse immune responses, including proinflammatory cytokine responses, interferon responses, apoptosis and autophagy (Smith 2021).

The cGAS-cGAMP-STING pathway is a major pathway for detecting pathogen-derived DNA in vertebrates. However, the role of the cGAS pathway is not limited to antimicrobial defense. cGAS can be activated by self-DNA, including genomic and mitochondrial DNA (Zierhut and Funabiki 2020). cGAS is a universal DNA sensor and cannot discriminate self from non-self DNA. Pathological stimulation induces mtDNA release into the cytosol, which is recognized by the DNA sensor cGAS, and activates the cGAS-cGAMP-STING pathway (Ablasser and Chen 2019; Li and Chen 2018). A recent analysis of the level of ccf-mtDNA and degree of STING activation during sepsis-induced acute lung injury indicated that STING activation plays a pivotal role in mtDNA-mediated lung injury by inducing an inflammatory storm and disturbing autophagy. These findings highlighted unique features of ccf-mtDNA that are recognized by the STING pathway of macrophages in sepsis-related acute lung injury. These findings elucidate the role of cGAS-STING-mediated mtDNA pathway in self-injurious and anti-regenerative responses of the endothelium during murine acute lung injury (Huang et al. 2020; Liu et al. 2021). Moreover, self-DNA leaked from mitochondria can serve as a cGAS ligand to activate this pathway in lung diseases such as cystic fibrosis, chronic obstructive pulmonary disease,
idiopathic pulmonary fibrosis, and asthma (Ma et al. 2020).

SARS-CoV-2 ORF9b protein interacts with multiple components of the several signaling pathways such as STING, and negatively regulates antiviral immunity and thus facilitates viral replication (Han et al. 2021). SARS-CoV-2 could induce the formation of multineucleate syncytiot by cell–cell fusion during infection. These micronuclei could provide an efficient way for the SARS-CoV-2 RNA virus to activate IFN response via the cGAS–STING signaling pathway (Ren et al. 2021). Analysis indicated that regulating the upstream of the cytokines production such as the cGAS–cGAMP–STING pathway could consider as a potential therapeutic target preventing cytokine storm in COVID-19 (Deng et al. 2020). There is evidence to suggest that most caspase family members can regulate the cGAS–STING signaling pathway negatively. Considering the interactions between the cGAS–STING signaling and COVID-19, it seems that the inhibition of caspase-mediated cleavage of cGAS–STING could be beneficial for reducing tissue damage in responses to SARS-CoV-2 infection (Xiong et al. 2021).

5. MtDNA and inflammasome activation and regulation in COVID-19

Inflammasomes are the multiprotein oligomers that act as the innate immune system receptors when encountered with pathogens and some host proteins. Both exogenous and endogenous ligands can activate inflammasome and inflammatory cascade (Zheng et al. 2020). The inflammasomes regulate the activation of the Caspase-1, which induces the cell death process known as pyroptosis, and secretion of interleukins and inflammasome and inflammatory cascade (Zheng et al. 2020). There is evidence to suggest that most caspase family members can regulate the cGAS–STING signaling pathway negatively. Considering the interactions between the cGAS–STING signaling and COVID-19, it seems that the inhibition of caspase-mediated cleavage of cGAS–STING could be beneficial for reducing tissue damage in responses to SARS-CoV-2 infection (Xiong et al. 2021).

5.1. MtDNA and NLRP3 inflammasome in COVID-19

NLR (nucleotide-binding domain leucine-rich repeat containing) proteins are a family of innate immune receptors that contribute to the regulation and induction of antimicrobial immune responses (Ye and Ting 2008). The genomic mining of evolutionary conserved regions with structural similarity and functional overlaps has led to the discovery of a large gene family encoding proteins with a characteristic arrangement of NLR. There is several number of NLR proteins in mammalian cells (Eliav et al. 2013; Ting et al. 2008).

The NLRP3 is the key member of NLR proteins which activates in response to diverse stimuli. Both mtDNA and mitochondrial ROS (mtROS) directly induce the activation of NLRP3 inflammasome (Ye and Ting 2008). Mitochondrial dysfunction and programmed cell death lead to release of mtDNA into the cytosol. Ccf-mtDNA induced activation of the NLRP3 inflammasome and triggered macrophages for orchestration of immune response (Shimada et al. 2012; Zhong et al. 2018). Genetic and pharmacological evidence elucidate the critical role of the NLRP3 inflammasome in the progression of several pulmonary diseases and viral and bacterial infections of the respiratory tract (De Nardo et al. 2014; Grailer et al. 2014). Activation of NLRP3 inflammasome by ccf-mtDNA can induce pulmonary inflammation and injury through TLR9, p38 MAPK and NF-κB pathways in macrophages (Wu et al. 2019).

Heterogenous and inter-individual variations in clinical manifestations of COVID-19 patients could be attributed to deleterious effects of inflammasome activation, which is related to the fitness of the immune system of the (Fulop et al. 2017). Recent evidence suggested that SARS-CoV-2 might directly activate NLRP3 inflammasome and subsequent upregulation of downstream Caspase-1, and inflammatory cytokines in COVID-19 patients (Amin et al. 2021; Pan et al. 2021; van den Berg and Te Velde 2020). Fig. 2 illustrates the role of mtDNA in the activation of NLRP3 inflammasome in SARS-CoV-2 infection. Investigation of the effect of SARS-CoV-2 nucleocapsid protein (N) indicated that N protein could directly interact with NLRP3 and promote the assembly and activation of NLRP3 inflammasome in cultured cells and mouse models.

As a result, large amounts of cytokines are released, which play a critical role in initiating “cytokine storm” in COVID-19. These findings suggest that SARS-CoV-2 N protein may cause lung injury by inducing the production of proinflammatory factors such as IL-1β and IL-6. Therefore, this kind of inflammasome appears to be a potential therapeutic target for COVID-19 (Pan et al. 2021). Overactivation of NLRP3 inflammasome in patients with uncontrolled diabetes could be one of the major contributing factors for COVID-19 severity (Lambardi et al. 2020). Delay of INF-γ response and lower CD4 + and CD8 + cell numbers as the result of NLRP3 inflammasome overactivity may make diabetic patients vulnerable to adverse clinical outcomes in COVID-19 infection (Lambardi et al. 2020). The crucial role of NLRP3 in the pathogenesis of SARS-CoV-2 highlights the therapeutic importance of the NLRP3 inflammasome in COVID-19. Therefore, it seems that pharmacological inhibitors and long non-coding RNAs (IncRNAs) might help reduce the clinical manifestations of SARS-CoV-2 (Freedman and Swartz 2020; Paniri and Akhavan-Niaki 2020; Shah 2020).

5.2. MtDNA and AIM2 inflammasome in COVID-19

Absent in melanoma 2 (AIM2) cytosolic innate immune sensors detect the presence of double-strand DNA, and lead to the assembly of the inflammasome. AIM2 inflammasome promotes the secretion of the cytokines IL-1β and IL-18 and also initiates pyroptosis.. AIM2 inflammasome plays a critical role as a guardian of cellular integrity in inflammatory and infectious diseases (Sharma et al. 2019).

Recent findings unraveled that ccf-mtDNA induces AIM2 inflammasome-dependent caspase-1 activation and IL-1β and IL-18 secretion in various human diseases such as type 2 diabetes, and nonalcoholic fatty liver disease (Bae et al. 2019; Cataño Canizalez et al. 2018; Xu et al. 2021). Based on our current knowledge, influenza virus-induced oxidized mtDNA can stimulate AIM2-dependent IL-1β secretion in macrophages; in addition, AIM2 inflammasome plays a critical role in virus-induced lung injury and mortality (Moriyama et al. 2020; Zhang et al. 2017). Recent evidence showed that monocytes in the blood of patients with SARS-CoV-2 infection activate AIM2 inflammasome following the caspase-1, gasdermin D (GSDMD) cleavage and trigger immune response (Junqueira et al. 2021). Taken together, the findings of the current studies indicated that mtDNA could play a major role in the activation of AIM2 inflammasome and following inflammatory response and cytokine storm during severe COVID-19.

6. Mitochondria, as an Emerging therapeutic target in COVID-19

There are many avenues involving mitochondria and their roles in the pathogenesis of SARS-CoV-2. Emerging evidence suggests that COVID-19 highjacks mitochondria of immune cells. Mitochondria centralize several critical innate immune responses through the
Damaged cells by manipulated mesenchymal stem cells (MSCs) demonstrated that the increased expression of MAVS proteins could provide promising insights by activation of MAVSs and inflammasome formation indicated that mitochondria in inducing immune responses. Moreover, elevated levels of ccf-mtDNA have been reported as an early indicator of the prognosis and severity in viral infections and COVID-19. We discussed the latest findings concerning the central role of mtDNA-related signaling pathways in COVID-19. Based on our current knowledge, mtDNA is recognized by TLR9 and cGAS-STING, which serve as fundamental mtDNA-related signaling pathways in the induction of immune response and aggressive cytokine storm during SARS-CoV-2 infection. Activation of NLRP3 and AIM2 inflammasomes stimulate the production of the proinflammatory cytokines and orchestrate the innate and adaptive immune responses. However, further studies are needed to delineate the detail of the molecular mechanism towards therapeutic approaches for COVID-19.

**Funding Sources.**

This work was supported by Tabriz University of Medical Sciences [grant code 68454].

**CRediT authorship contribution statement**

**A. Mahmoodpoor:** Project administration, Conceptualization, Funding acquisition. **Sarvin Sanaie:** Project administration, Conceptualization, Funding acquisition, Writing – review & editing. **Zohreh Ostadi:** Writing – review & editing. **Maqsoud Eskandari:** Writing – review & editing. **Nazila Behrouzi:** Writing – review & editing. **Roqayah Asghari:** Writing – review & editing. **Ahmad Zahirinia:** Investigation, Validation, Nasim Sohrabifar: Conceptualization, Investigation, Validation, Writing – original draft. **Somayeh Kazeminasab:** Conceptualization, Investigation, Validation, Writing – original draft.

**Declaration of Competing Interest**

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

**References**

Ablaser, A., Chen, Z.J., 2019. cGAS in action: Expanding roles in immunity and inflammation. Science 363 (6431). https://doi.org/10.1126/science.aan6657.

Ablaser, A., Hur, S., 2020. Regulation of cGAS-and RLR-mediated immunity to nucleic acids. Nat. Immunol. 21 (1), 17–29.

Amin, S., Akhtar, S., Rahman, M.M., Chowdhury, M.M.H., 2021. NLRP3 inflammasome activation in COVID-19: an interlink between risk factors and disease severity. Microbes and Infection:104913.

Angelopoulos, A., Alexandris, N., Konstantinou, E., Mesiakaris, K., Zanidis, C., Farsalinos, K., Poulas, K., 2020. Imiquimod-a toll like receptor 7 agonist is an ideal option for management of COVID 19. Environ. Res. 188, 109858. https://doi.org/10.1016/j.envres.2020.109858.

Ayala, D.-J.-M.-F., Navas, P., López-Lluch, G., 2020. Age-related mitochondrial dysfunction as a key factor in COVID-19 disease. Exp. Gerontol.:111147.
Babajani, A., Hosseini-Monfared, P., Abbaspour, S., Jamsabdi, E., Niknejad, H., 2021. Targeted Mitochondrial Therapy with Over-expressed MAVS Protein from Mesenchymal Stromal Cell: A New Therapeutic Approach for COVID-19. Front. Cell Dev. Biol. 9, 1475.

Bae, J.H., Jo, S.I., Kim, S.J., Lee, J.M., Jeong, J.H., Kang, J.S., Cho, N.-J., Kim, S.S., Lee, E.Y., Moon, J.-S., 2019. Circulating cell-free mtDNA contributes to AIM2 inflammasome-mediated inflammation in patients with type 2 diabetes. Cells 8 (4), 328. https://doi.org/10.3390/cells8040328.

Barton, G.M., Kagan, J.C., Medzhitov, R., 2006. Intracellular localization of Toll-like receptor 9 prevents recognition of self DNA but facilitates access to viral DNA. Nat. Immunol. 7 (1), 49–56.

Belgaoune, S.M., Paz, S., Hiess, J., 2011. Orchestrating the interferon antiviral response through the mito-chondrial antiviral signaling (MAVS) adapter. Curr. Opin. Immunol. 23 (5), 544–572.

Besser, G.F., Garssen, J., 2021. TLR9 and COVID-19: a multidisciplinary theory of a current puzzle. Semin. Immunol. 56, 100871. https://doi.org/10.1016/j.smim.2021.100871.

Carty, M., Bowie, A.G., 2010. Recent insights into the role of Toll-like receptors in viral infection. Clin. Exp. Immunol. 161 (3), 397–406.

Cantin-Carisse, Y., Ureña-Escoto, R., Portales Perez, D., Bastian, Y., Rodriguez Rivera, J., Gonzalez Amaro, R., Enciso Moreno, J., Garcia Hernandez, M., 2018. Increased levels of AIM2 and circulating mitochondrial DNA in type 2 diabetes. Iranian Journal of Immunology 15, 142–155.

Chinnery, P.F., Samuels, D.C., Elson, J., Turnbull, D.M., 2002. Accumulation of mtDNA point mutations in aging and age-related diseases. Front. Aging Neurosci. 12, 502. https://doi.org/10.3389/fnagi.2020.00058.

Chow, H., Callaway, J.B., Ting, Y.-J., 2015. Inflammasomes: mechanism of action, role in disease, and therapeutics. Nat. Med. 21 (7), 677–687.

Han, L., Zhang, M.-W., Deng, J., Zheng, Y.i., Zhang, J., Nan, M.-L., Zhang, X.-J., Gao, C., Wang, P.-H., 2021. SARS-CoV-2 ORF6 antagonizes type I and III interferons by targeting multiple components of the RIG-I/MDA-5-VIPP1 complex and (GAS)-STING signaling pathways. J. Med. Virol. 93 (9), 5376–5389.

Harrington, J.S., Huh, J.-W., Schenck, E.L., Nakahira, K., Siempos, I.I., Choi, A.M.K., 2019. Circulating mitochondrial DNA as predictor of mortality in critically ill COVID-19 patients. Front. Immunol. 10, 1130. https://doi.org/10.3389/fimmu.2019.01130.

Hauser, C.J., Otterbein, L.E., 2018. Danger signals from mitochondrial DAMPs in trauma and post-injury sepsis. Eur. J. Trauma Emerg. Surg. 44 (4), 317–324.

Hoffmann, M., Klüpfel, S., Krüger, N., Tschiersch, E., Eichler, S., Schmidt, S., Nirschl, A., Nitsche, A., Drosten, C., Pöhlmann, S., 2020. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181 (2), 271–280.

Hung, L.S., Hong, Z., Wu, W., Xiong, Z., Zhuo, M., Gao, X., Rehman, J., Malick, A.B., 2020. An RNA-seq study in lung samples of non-COVID-19 patients suggests a YAP-mediated cell proliferation program to promote inflammatory injury. Immunity 52 (3), 475–485.e6.

Itakagi, K., Kei, I., Konczen, B., Kim, H.I., Park, J., Kaczmarek, E., Hauser, C.J., 2021. Role of Mitochondria-Derived Danger Signals Released After Infection in Systemic Inflammation and Sepsis. Antioxid. Redox Signal. 35 (15), 1273–1290.

Juarez, C. Crespo A, Ranjarb S, Inger J, Barry P, David S, de Lacerda LB, Lewandowski M, Clark SA, Ho F (2021) SARS-CoV-2 infects bone monocytes to activate NLRP3 and AIM2 inflammasomes, pyroptosis and cytokine release. medRxiv.

Kaur, S., Yang, A., Abbasi, M.N., Hu, X., Zhao, Y., Zyu, C., Hui, C., 2020. Mitochondrial DNA: a key regulator of anti-microbial innate immunity. Genes 11 (1), 86. https://doi.org/10.3390/genes11010086.

Khan, M., Syed, G.H., Kim, S.-J., Siddiqui, A., 2015. Mitochondrial dynamics and viral infections: a close nexus. Biochimica et Biophysica Acta (BBA)-Molecular Cell Res. 1851 (1), 2822–2833.

Koshiba, T., Yanagi, K., Kawabata, S.-I., 2011. Mitochondrial membrane potential is required for MAVS-mediated antiviral signaling. Sci. Signal. 4 (158) https://doi.org/10.1126/scisignal.2001147.

Kowaltowski, A.J., de Souza-Pinto, N.C., Castilho, R.F., Vercesi, A.E., 2009. Mitochondria and mitochondrial DNA as targets of AGEs and superoxides. Biochem. Biophys. Res. Commun. 387 (4), 5607–5609.

Eisen, S., Uskucu, M., 2021. Role of Mitochondrial in Viral Infections. Life 11 (5), 232. https://doi.org/10.3390/life11050232.

Elinav, E., Strowig, T., Henao-Mejia, J., Flavell, R., 2011. Regulation of the antimicrobial response by NLR proteins. Immunity 34 (5), 655–679.

Feng, D., Xu, H., Li, X., Wu, Y., Wang, H., Shi, L., Li, L., Zou, F., 2016. An association analysis between mitochondrial DNA content, G10398A polymorphism, HIV infection, and the prognosis of cervical cancer in the Chinese Han population. Tumor Biology 37 (4), 5589–5607.

Ferreira, A.C., Soares, V.C., de Avezedo-Quintanilha, I.G., Dias, S.S., Fintelman-Rodrigues, N., Sacramento, C.C., Mattos, M., de Freitas, C.S., Temerozo, J.R., 2021. SARS-CoV-2 engages inflammasome and pyroptosis in human pneumocytes at very early stage of SARS-CoV-2 infection. J. Immunol. 207, 1435–1446.

Freeman, T.L., Swartz, T.H., 2020. Targeting the NLRP3 inflammasome in severe COVID-19. Front. Immunol. 11, 1518.

Fulop, T., Matzinger, P., 2008. Viral infection and iron metabolism. Nat. Rev. Immunol. 8 (1), 54–64.

Galimberti, D., Hong, K., Jiang, Y., 2014. Mitochondrial DNA methylation and aging. Aging Cell 13 (2), 167–174.

Ganji, R., Reddy, P.H., 2021. Impact of COVID-19 on mitochondrial-based immunity in aging and age-related diseases. Front. Aging Neurosci. 12, 502.

Gordon, D.E., Jiang, G.M., Boudhodid, M., Xu, J., Obernier, K., White, K.M., O'Meara, J., Li, J., Mittal, V.V., Grewal, M., Fratila, V., Tummino, T.A., Hüttenhain, R., Koelle, R.M., Richards, A.L., Tulucuoglu, B., Fournier, H., Batra, J., Haas, K., Modak, M., Kim, M., Haas, P., Polacco, J.B., Braberg, H., Fabius, J.M., Eckhard, M., Souchay, M., Bennett, M.J., Cakir, M., McGregor, M.J., Li, Q., Meyer, B., Roesch, F., Valleri, T., Mac Kain, A., Miorin, L., Moreno, E., Naing, Z.C.C., Zhou, Y., Peng, J., Bao, M., Vanhoutte, J.M., Dai, S.A., Barrio-Hernández, I., Memon, D., Hernandez-Armenta, C., Lyu, J., Mathy, C.P.C., Perica, T., Pilla, K.B., Ganesan, S.J., Saltzberg, D.J., Rakesh, R., Liu, X., X., Rosenthal, S.B., Calviello, V., Venkataraman, S., Libby-Lagoo, J., Lin, Y., Huang, K.P., Yu, Yong, B., Mohanty, M., Safari, M., Uz, F.S., Cai, K., Savar, S.N., Tran, Q.D., Shengjuler, D., Fletcher, S.J., O’Neal, M.C., Cai, Y., Chang, J.C.I., Broadhurst, D.J., Klippstein, S., Sharp, P.P., Wenzel, N.A., Kuzugzhagay, O., Dang, W.-H., Trenker, R., Young, J.M., Cavero, D.A., Hiatt, J., Roth, L.T., Rathore, U., Subramanian, A., Noak, J., Hubert, M., Stroud, R.M., Frankel, A.D., Dinh, K., Dobrzanski, S., Imura, S., Guo, H., Callaway, J.B., Ting, Y.-J., 2020. Inflammasomes: mechanism of action, role in disease, and therapeutics. Nat. Med. 26 (1), 677–687.
activation to induce hyperinflammation. Nat. Commun. 12 (1) https://doi.org/10.1038/s41467-021-25031-8.

Panir, A., Akhavan-Nia, H. 2020. Emerging role of IL-6 and NLRP3 inflammasome as potential therapeutic targets to combat COVID-19: Role of lncRNAs in cytokine storm modulation. Life Sci. 118114, 257, 118114. https://doi.org/10.1016/j.lfs.2020.118114.

Piantadosi, C.A., 2020. Mitochondrial DNA, oxidants, and innate immunity. Free Radical Biol. Med. 152, 455–461.

Pinti, M., Cevenini, E., Nasi, M., De Biasi, S., Salvioi, S., Monti, D., Benatti, S., Gibellini, L., Cotichini, R., Sazio, M.A., Trenti, T., Franceschi, C., Giorgetti, A., 2014. Circulating mitochondrial DNA increases with age and is a familiar trait: Implications for 'inflamm-aging'. Eur. J. Immunol. 44 (5), 1552–1562.

Ren, H., Ma, C., Peng, H., Zhang, B., Zhou, L., Su, Y., Gao, X., Huang, H., 2021. Microcircuits production, activation of DNA damage response and cGAS-STING signaling in synecytia induced by SARS-CoV-2 infection. Biology Direct 16, 1–10.

Ren Z, Zhang X, Ding T, Zhong Z, Hu H, Xu Z, Deng J (2020) Mitochondrial dynamics imbalance: a strategy for promoting viral infection. Frontiers in Microbiology:1992.

Riley, J.S., Tai, S.W., 2020. Mitochondrial DNA in inflammation and immunity. EMBO Rep. 21, e49799.

Saleh, J., Peyssonnaux, C., Singh, K.K., Edeas, M., 2020. Mitochondria and microbiota dysfunction in COVID-19 pathogenesis. Mitochondrion 54, 1–7.

Salmieri, A., Ojala, J., Kaarniranta, K., Kauppinen, A., 2012. Mitochondrial dysfunction and oxidative stress activate inflammasomes: impact on the aging process and age-related diseases. Cell. Mol. Life Sci. 69 (18), 2999–3013.

Schafel, S.T., Franken, L., Adamzik, M., Schuman, B., Scheng, A., Engler, A., Schönborn, N., Walden, J., Koch, S., Baba, H.A., Steinmann, J., Westendorf, A.M., Fandrey, J., Bieber, T., Kerts, C., Frede, S., Peters, J., Limmer, A., 2016. Mitochondrial DNA: An Endogenous Trigger for Immune Paralysis. Anesthesiology 124 (4), 923–933.

Scorzi D, Cano M, Alcorn JF, Chen K, Fan S, Hoffman H, Hugot JP, Inohara N, MacKenzie A, Maltais LJ, Nunez G, Ongara Y, Otten LA, Philpot D, Reed J, C Reith W, Schreiber S, Steimle V, Ward P, 2008. The NLR gene family: a standard nomenclature. Immunity 28 (3), 285–287.

Upton, J., Chan, F.-M., 2014. Staying alive: cell death in antiviral immunity. Mol. Cell 54 (2), 273–280.

Valdés-Aguayo JJ, Garza-Veloz J, Vargas-Rodriguez JR, Martínez-Vázquez MC, Avila-Carrasco I, Bernal-Silva S, González-Fuentes C, Comas-García A, Alvarado-Hernández DE, Centeno-Ramírez AS (2021) Peripheral Blood Mitochondrial DNA Levels Were Modulated by SARS-CoV-2 Infection Severity and Its Lesening Was Associated With Mortality Among Hospitalized Patients With COVID-19. Frontiers in Cellular and Infection Microbiology:1285.

van den Berg, D.F., Te Velde, A.A., 2020. Severe COVID-19: NLRP3 inflammasome dysregulated. Front. Immunol. 11, 1580.

Vazquez, C., Horner, S.M., 2015. MAVS coordination of antiviral innate immunity. J. Virol. 89 (14), 6974–6977.

Verhein, K.C., Vellers, H.L., Kleeberger, S.R., 2018. Inter-individual variation in health and disease associated with pulmonary infectious agents. Mamm. Genome 29 (1-2), 38–47.

Wang, C., Horby, P.W., Hayden, F.G., Gao, G.F., 2020. A novel coronavirus outbreak of global health concern. The lancet 395 (10223), 470–473.

Wang, Y., McLean, A.S., 2022. The Role of Mitochondria in the Immune Response in Critical Illness. Crit. Care 26, 1–6.

West, A.P., Shadel, G.S., Ghosh, S., 2011. Mitochondria in innate immune responses. Nat. Rev. Immunol. 11 (6), 389–402.

Wu, G., Zhu, Q., Zeng, J., Gu, X., Miao, Y., Xu, W., Lv, T., Song, Y., 2019. Extracellular mitochondrial DNA promote NLRP3 inflammasome activation and induce acute lung injury through TLR9 and NF-κB. Journal of thoracic disease 11 (11), 4816–4828.

Xiong, Y., Tang, Y.-D., Zheng, C., 2021. The crosstalk between the capase family and the cGAS-STING signaling pathway. J. Mol. Cell Biol. 13 (10), 739–747.

Xu, L., Zhou, Z., Che, J., Wang, H., Yang, W., Zhou, W., Zhao, H., 2021. Mitochondrial DNA enables AIM2 inflammasome activation and hepatocyte pyroptosis in nonalcoholic fatty liver disease. American Journal of Physiology-Gastrointestinal and Liver. Physiology 330 (6), G1043-G1044.

Yang, J., Zheng, Y., Gou, X., Pu, K., Chen, Z., Gao, Q., Ji, R., Wang, H., Wang, Y., Zhou, Y., 2020. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. International journal of infectious diseases 94, 91–95.

Ye, Z., Ting, J.Y., 2008. NLR, the nucleotide-binding domain leucine-rich repeat containing gene family. Curr Opin Immunol 20 (1), 3–9.

Yuki, K., Fujioi, M., Koutsogiannis, S., 2020. COVID-19 pathophysiology: A review. Clinical medicine 215, 108427. https://doi.org/10.1016/j.clinmed.2020.108427.

Zhang, H., Liao, J., Alcorn, J.F., Chen, K., Fan, S., Pilewski, J., Liu, A., Chen, W., Kolls, J. K., Wang, J., 2017. AIM2 inflammasome is critical for influenza-induced lung injury and mortality. J. Immunol. 198 (11), 4383–4393.

Zhang, J.-J., Dong, X., Gao, Y.-Y., Yuan, Y.-D., Yang, Y.-B., Yan, Y.-Q., Akdis, C.A., Gao, Y.-D., 2020a. Clinical characteristics of 140 patients infected with SARS-Cov-2 in Wuhan, China. Allergy 75 (7), 1730–1741.

Zhang, Q., Roos, M., Chen, Y., Sumi, Y., Sural, T., Junger, W., Brohi, K., Itagaki, K., Hauser, C.J., 2010. Circulating mitochondrial DAMPs cause inflammatory responses to injury. Nature 464 (7285), 104–107.

Zhang, R., Wang, X., Li, D., Xi, M., Bao, N., Liu, C., Reiter, R.J., 2020b. COVID-19: Melatonin as a potential adjuvant treatment. Life Sci. 250, 117583. https://doi.org/10.1016/j.lfs.2020.117583.

Zhang, X., Bai, X.-C., Chen, Z.-J., 2020c. Structures and mechanisms in the cGAS-STING innate immunity pathway. Immunity 53 (4), 43–53.

Zhang, D., Liwinski, T., Elnav, E., 2020. Inflammasome activation and regulation: toward a better understanding of complex mechanisms. Cell Discov 6, 36.

Zhang, Z., Liang, S., Sanchez-Lopez, E., He, F., Shalapour, S., Lin, X.-J., Wong, J., Ding, S., Seki, E., Schnabl, B., Hevener, A.L., Greenberg, H.B., Kisselova, T., Karin, M., 2018. New mitochondrial DNA synthesis enables NLRP3 inflammasome activation. Nature 560 (7477), 198–203.

Zierath, R., Funahashi, H., 2020. Regulation and Consequences of eGAS Activation by Self-DNA. Trends Cell Biol 30 (8), 594–605.